Dilaudid®
Hydromorphone · oral tablet, oral solution
Analgesics
Approved uses
Pain severe enough to require an opioid analgesic, when alternative treatments are inadequate (non-ocular; the only labeled use)
Tablets 2 mg to 4 mg PO q4-6h PRN; oral solution 2.5 mg to 10 mg (2.5 mL to 10 mL) PO q3-6h PRN
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to hydromorphone, hydromorphone salts, any other components of the product, or sulfite-containing medications (e.g., anaphylaxis)
2 mg, 4 mg and 8 mg tablets in bottles of 100 (4 mg also in bottles of 500); oral solution 5 mg/5 mL (1 mg/mL) in 473 mL bottles
Full opioid agonist, relatively selective for the mu-opioid receptor, although it can bind other opioid receptors at higher doses; analgesia is its principal action and, as with all full agonists, there is no analgesic ceiling. Ocularly relevant pharmacodynamics: miosis occurs even in total darkness, while marked mydriasis rather than miosis may appear with hypoxia in overdose.
Warnings & Precautions
- Addiction, abuse, and misuse: Boxed warning. Schedule II opioid; addiction can occur at recommended doses. Assess risk before prescribing and reassess throughout therapy.
- Life-threatening respiratory depression: Boxed warning. Risk is greatest at initiation and after any dosage increase; opioids also raise the risk of central sleep apnea in a dose-dependent fashion. Overestimating the dosage when converting from another opioid can result in a fatal overdose with the first dose. Discuss the importance of having access to an opioid overdose reversal agent (e.g., naloxone, nalmefene).
- Profound sedation, respiratory depression, coma, and death: Boxed warning. These may result from concomitant use with benzodiazepines or other CNS depressants, including alcohol, gabapentinoids, muscle relaxants, and other opioids. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
- Accidental ingestion: Boxed warning. A single dose, especially in a child, can produce a fatal overdose.
- Risk of medication errors: Boxed warning. Dosing errors due to confusion between mg and mL, and with other hydromorphone oral solutions of different concentrations, can result in accidental overdose and death; when prescribing the oral solution, include both the total dose in mg and the total dose in volume.
- Neonatal opioid withdrawal syndrome: Boxed warning. Extended use in pregnancy can cause neonatal withdrawal, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
- Opioid analgesic REMS: Boxed warning. Prescribers are strongly encouraged to complete a REMS-compliant education program and to counsel on risks, storage, and disposal at every prescription.
- Respiratory depression in chronic pulmonary disease: Significant chronic obstructive pulmonary disease or cor pulmonale, substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression raise the risk of decreased respiratory drive including apnea, even at recommended dosages. Life-threatening respiratory depression is more likely in elderly, cachectic, or debilitated patients. Regularly evaluate these patients, or consider non-opioid analgesics.
- Increased intracranial pressure: CO2 retention from reduced respiratory drive can further raise intracranial pressure in susceptible patients, including those with brain tumors, and opioids may obscure the clinical course of head injury; avoid in impaired consciousness or coma.
- Allergic-type reactions to sulfites: Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people; sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
- Opioid-induced hyperalgesia and allodynia: Paradoxical increase in pain or pain sensitivity, reported with both short-term and longer-term use; if suspected, carefully consider decreasing the dose of the current opioid or opioid rotation.
- Severe hypotension: May cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. Avoid in circulatory shock, where it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Adrenal insufficiency: Reported with opioid use, more often after more than one month; confirm by testing, give physiologic corticosteroid replacement, and wean the opioid.
- Gastrointestinal complications: May cause spasm of the sphincter of Oddi, and opioids may cause increases in serum amylase; regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. Opioid-induced esophageal dysfunction (OIED) has been reported, and its risk may increase as the dose and/or duration of opioids increases.
- Serotonin syndrome or opioid toxicity: Not recommended in patients taking an MAOI or within 14 days of stopping one; MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity.
- Withdrawal: Do not abruptly discontinue or rapidly reduce in a physically dependent patient; gradually taper, for example by no greater than 10% to 25% of the total daily dose at intervals of every 2 to 4 weeks. Avoid mixed agonist/antagonist (e.g., pentazocine, nalbuphine, butorphanol) or partial agonist (e.g., buprenorphine) analgesics, which may reduce the analgesic effect and/or precipitate withdrawal symptoms.
- Increased risk of seizures: May increase seizure frequency in patients with a seizure disorder and the risk of seizures in other settings associated with them.
- Risks of driving and operating machinery: May impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects and know how they will react to the medication.
Common Side Effects
The most common adverse effects are lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus; these effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain. Serious adverse reactions include respiratory depression and apnea and, to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest. Less frequently observed reactions include blurred vision, diplopia, miosis, and visual impairment, as well as headache, tremor, nystagmus, increased intracranial pressure, syncope, presyncope, and involuntary muscle contractions. Postmarketing reports include serotonin syndrome with serotonergic drugs, adrenal insufficiency (more often after more than one month of use), anaphylaxis, hyperalgesia and allodynia, hypoglycemia, and opioid-induced esophageal dysfunction.
Pregnancy: No human data to inform a drug-associated risk of major birth defects or miscarriage; animal studies showed neural tube defects in hamsters, soft tissue and skeletal abnormalities in mice, and reduced pup survival and body weight in rats. Based on animal data, advise pregnant women of the potential risk to a fetus. Extended use in pregnancy can cause neonatal opioid withdrawal syndrome; not recommended during or immediately prior to labor, when other analgesic techniques are more appropriate.
Lactation: Low levels of opioid analgesics have been detected in human milk; monitor the breastfed infant for excess sedation and respiratory depression, and for withdrawal when maternal use or breastfeeding stops.
Safety and effectiveness in pediatric patients have not been established.